(HBIO) Harvard Bioscience - Ratings and Ratios

Harvard Bioscience, Inc. (NASDAQ:HBIO) is a global leader in developing, manufacturing, and distributing cutting-edge technologies, products, and services tailored for life science applications. The company serves a diverse range of clients, including research scientists in pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, and contract research organizations. Its product portfolio encompasses cellular and molecular technology solutions, including infusion pumps, electroporation instruments, amino acid analyzers, and spectrophotometers. Additionally, it offers precision scientific instruments such as data acquisition systems, micro electrode array solutions, and in vitro and in vivo recording systems.

The company’s preclinical product line includes advanced platforms for physiological data collection, such as implantable and wearable telemetry systems for monitoring cardiovascular, central nervous system, respiratory, and metabolic data. It also provides behavioral research tools, isolated organ and surgical instruments, and turn-key respiratory solutions, including plethysmograph chambers and physiological signal analysis software. Inhalation and exposure systems, along with GLP-capable data acquisition and analysis systems, further complement its offerings. Harvard Bioscience markets its products under well-established brands like Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.

Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience has a long-standing reputation for innovation and reliability in the life sciences industry. Its extensive distribution network includes direct sales, websites, and partnerships with distributors, ensuring global reach and accessibility for its clients.